Evaluation of lysophosphatidic acid in vaginal fluid as a biomarker for ovarian cancer: A pilot study
There remains a need to differentiate between women with a benign or a malignant adnexal mass prior to surgery. As part of an ongoing evaluation of vaginal fluid compounds as potential tumor biomarkers we evaluated whether vaginal lysophosphatidic acid (LPA) predicted the subsequent diagnosis of a m...
Uložené v:
| Vydané v: | European journal of obstetrics & gynecology and reproductive biology: X Ročník 2; s. 100012 |
|---|---|
| Hlavní autori: | , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Netherlands
Elsevier
01.04.2019
|
| Predmet: | |
| ISSN: | 2590-1613, 2590-1613 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | There remains a need to differentiate between women with a benign or a malignant adnexal mass prior to surgery. As part of an ongoing evaluation of vaginal fluid compounds as potential tumor biomarkers we evaluated whether vaginal lysophosphatidic acid (LPA) predicted the subsequent diagnosis of a malignant adnexal mass. In this prospective pilot study vaginal fluid was obtained from 100 post-menopausal women referred for evaluation of a suspicious adnexal mass and tested for LPA by ELISA. Clinical data and serum CA125 results were obtained only after completion of all laboratory testing. Twenty eight of the women were subsequently diagnosed with an ovarian malignancy, four had a borderline tumor and 68 had a benign diagnosis. Among women with a malignant ovarian mass, 11 (39.3%) had an endometrioid adenocarcinoma +/- Clear cell tumor components, 6 (21.4%) had a high grade serous carcinoma, 3 (10.7%) had a mucinous tumor, 2 each (7.1%) had a malignant mixed mesodermal or a granulosa tumor and 1 each (3.6%) had a Clear cell tumor, a mixed cell tumor, leimyosarcoma or metastatic adrenal tumor. Compared to the median vaginal LPA level in women with benign lesions (1.5 μM), LPA was significantly elevated only in women with endometrioid ovarian cancer (7.9 μM) (p = 0.0137). Of the 6 endometrioid tumors in which values for both plasma CA125 and vaginal LPA were available 5 were positive only for LPA while one was only CA125 positive. Detection of LPA in vaginal secretions may be of value for the noninvasive diagnosis of endometrioid ovarian malignancies in post-menopausal women. |
|---|---|
| AbstractList | There remains a need to differentiate between women with a benign or a malignant adnexal mass prior to surgery. As part of an ongoing evaluation of vaginal fluid compounds as potential tumor biomarkers we evaluated whether vaginal lysophosphatidic acid (LPA) predicted the subsequent diagnosis of a malignant adnexal mass. In this prospective pilot study vaginal fluid was obtained from 100 post-menopausal women referred for evaluation of a suspicious adnexal mass and tested for LPA by ELISA. Clinical data and serum CA125 results were obtained only after completion of all laboratory testing. Twenty eight of the women were subsequently diagnosed with an ovarian malignancy, four had a borderline tumor and 68 had a benign diagnosis. Among women with a malignant ovarian mass, 11 (39.3%) had an endometrioid adenocarcinoma +/− Clear cell tumor components, 6 (21.4%) had a high grade serous carcinoma, 3 (10.7%) had a mucinous tumor, 2 each (7.1%) had a malignant mixed mesodermal or a granulosa tumor and 1 each (3.6%) had a Clear cell tumor, a mixed cell tumor, leimyosarcoma or metastatic adrenal tumor. Compared to the median vaginal LPA level in women with benign lesions (1.5 μM), LPA was significantly elevated only in women with endometrioid ovarian cancer (7.9 μM) (p = 0.0137). Of the 6 endometrioid tumors in which values for both plasma CA125 and vaginal LPA were available 5 were positive only for LPA while one was only CA125 positive. Detection of LPA in vaginal secretions may be of value for the noninvasive diagnosis of endometrioid ovarian malignancies in post-menopausal women. Keywords: Adnexal mass, CA125, Endometrioid ovarian cancer, Lysophosphatidic acid There remains a need to differentiate between women with a benign or a malignant adnexal mass prior to surgery. As part of an ongoing evaluation of vaginal fluid compounds as potential tumor biomarkers we evaluated whether vaginal lysophosphatidic acid (LPA) predicted the subsequent diagnosis of a malignant adnexal mass. In this prospective pilot study vaginal fluid was obtained from 100 post-menopausal women referred for evaluation of a suspicious adnexal mass and tested for LPA by ELISA. Clinical data and serum CA125 results were obtained only after completion of all laboratory testing. Twenty eight of the women were subsequently diagnosed with an ovarian malignancy, four had a borderline tumor and 68 had a benign diagnosis. Among women with a malignant ovarian mass, 11 (39.3%) had an endometrioid adenocarcinoma +/− Clear cell tumor components, 6 (21.4%) had a high grade serous carcinoma, 3 (10.7%) had a mucinous tumor, 2 each (7.1%) had a malignant mixed mesodermal or a granulosa tumor and 1 each (3.6%) had a Clear cell tumor, a mixed cell tumor, leimyosarcoma or metastatic adrenal tumor. Compared to the median vaginal LPA level in women with benign lesions (1.5 μM), LPA was significantly elevated only in women with endometrioid ovarian cancer (7.9 μM) (p = 0.0137). Of the 6 endometrioid tumors in which values for both plasma CA125 and vaginal LPA were available 5 were positive only for LPA while one was only CA125 positive. Detection of LPA in vaginal secretions may be of value for the noninvasive diagnosis of endometrioid ovarian malignancies in post-menopausal women. There remains a need to differentiate between women with a benign or a malignant adnexal mass prior to surgery. As part of an ongoing evaluation of vaginal fluid compounds as potential tumor biomarkers we evaluated whether vaginal lysophosphatidic acid (LPA) predicted the subsequent diagnosis of a malignant adnexal mass. In this prospective pilot study vaginal fluid was obtained from 100 post-menopausal women referred for evaluation of a suspicious adnexal mass and tested for LPA by ELISA. Clinical data and serum CA125 results were obtained only after completion of all laboratory testing. Twenty eight of the women were subsequently diagnosed with an ovarian malignancy, four had a borderline tumor and 68 had a benign diagnosis. Among women with a malignant ovarian mass, 11 (39.3%) had an endometrioid adenocarcinoma +/- Clear cell tumor components, 6 (21.4%) had a high grade serous carcinoma, 3 (10.7%) had a mucinous tumor, 2 each (7.1%) had a malignant mixed mesodermal or a granulosa tumor and 1 each (3.6%) had a Clear cell tumor, a mixed cell tumor, leimyosarcoma or metastatic adrenal tumor. Compared to the median vaginal LPA level in women with benign lesions (1.5 μM), LPA was significantly elevated only in women with endometrioid ovarian cancer (7.9 μM) (p = 0.0137). Of the 6 endometrioid tumors in which values for both plasma CA125 and vaginal LPA were available 5 were positive only for LPA while one was only CA125 positive. Detection of LPA in vaginal secretions may be of value for the noninvasive diagnosis of endometrioid ovarian malignancies in post-menopausal women. There remains a need to differentiate between women with a benign or a malignant adnexal mass prior to surgery. As part of an ongoing evaluation of vaginal fluid compounds as potential tumor biomarkers we evaluated whether vaginal lysophosphatidic acid (LPA) predicted the subsequent diagnosis of a malignant adnexal mass. In this prospective pilot study vaginal fluid was obtained from 100 post-menopausal women referred for evaluation of a suspicious adnexal mass and tested for LPA by ELISA. Clinical data and serum CA125 results were obtained only after completion of all laboratory testing. Twenty eight of the women were subsequently diagnosed with an ovarian malignancy, four had a borderline tumor and 68 had a benign diagnosis. Among women with a malignant ovarian mass, 11 (39.3%) had an endometrioid adenocarcinoma +/- Clear cell tumor components, 6 (21.4%) had a high grade serous carcinoma, 3 (10.7%) had a mucinous tumor, 2 each (7.1%) had a malignant mixed mesodermal or a granulosa tumor and 1 each (3.6%) had a Clear cell tumor, a mixed cell tumor, leimyosarcoma or metastatic adrenal tumor. Compared to the median vaginal LPA level in women with benign lesions (1.5 μM), LPA was significantly elevated only in women with endometrioid ovarian cancer (7.9 μM) (p = 0.0137). Of the 6 endometrioid tumors in which values for both plasma CA125 and vaginal LPA were available 5 were positive only for LPA while one was only CA125 positive. Detection of LPA in vaginal secretions may be of value for the noninvasive diagnosis of endometrioid ovarian malignancies in post-menopausal women.There remains a need to differentiate between women with a benign or a malignant adnexal mass prior to surgery. As part of an ongoing evaluation of vaginal fluid compounds as potential tumor biomarkers we evaluated whether vaginal lysophosphatidic acid (LPA) predicted the subsequent diagnosis of a malignant adnexal mass. In this prospective pilot study vaginal fluid was obtained from 100 post-menopausal women referred for evaluation of a suspicious adnexal mass and tested for LPA by ELISA. Clinical data and serum CA125 results were obtained only after completion of all laboratory testing. Twenty eight of the women were subsequently diagnosed with an ovarian malignancy, four had a borderline tumor and 68 had a benign diagnosis. Among women with a malignant ovarian mass, 11 (39.3%) had an endometrioid adenocarcinoma +/- Clear cell tumor components, 6 (21.4%) had a high grade serous carcinoma, 3 (10.7%) had a mucinous tumor, 2 each (7.1%) had a malignant mixed mesodermal or a granulosa tumor and 1 each (3.6%) had a Clear cell tumor, a mixed cell tumor, leimyosarcoma or metastatic adrenal tumor. Compared to the median vaginal LPA level in women with benign lesions (1.5 μM), LPA was significantly elevated only in women with endometrioid ovarian cancer (7.9 μM) (p = 0.0137). Of the 6 endometrioid tumors in which values for both plasma CA125 and vaginal LPA were available 5 were positive only for LPA while one was only CA125 positive. Detection of LPA in vaginal secretions may be of value for the noninvasive diagnosis of endometrioid ovarian malignancies in post-menopausal women. |
| ArticleNumber | 100012 |
| Author | Caputo, Thomas A. Minis, Evelyn Nasioudis, Dimitrios Athanasiou, Aikaterini Witkin, Steven S. Holcomb, Kevin Chapman-Davis, Eloise Kanninen, Tomi T. Frey, Melissa K. Sisti, Giovanni |
| AuthorAffiliation | Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, New York, United States |
| AuthorAffiliation_xml | – name: Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, New York, United States |
| Author_xml | – sequence: 1 givenname: Evelyn surname: Minis fullname: Minis, Evelyn – sequence: 2 givenname: Kevin surname: Holcomb fullname: Holcomb, Kevin – sequence: 3 givenname: Giovanni surname: Sisti fullname: Sisti, Giovanni – sequence: 4 givenname: Dimitrios surname: Nasioudis fullname: Nasioudis, Dimitrios – sequence: 5 givenname: Tomi T. surname: Kanninen fullname: Kanninen, Tomi T. – sequence: 6 givenname: Aikaterini surname: Athanasiou fullname: Athanasiou, Aikaterini – sequence: 7 givenname: Melissa K. surname: Frey fullname: Frey, Melissa K. – sequence: 8 givenname: Eloise surname: Chapman-Davis fullname: Chapman-Davis, Eloise – sequence: 9 givenname: Thomas A. surname: Caputo fullname: Caputo, Thomas A. – sequence: 10 givenname: Steven S. surname: Witkin fullname: Witkin, Steven S. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31396597$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktvEzEUhUeoiD7oL0BCXrJJ8PU8PGaBVFWFVqrEBtbWHT8SB8ce7JmI_HvcpEUtC1a2js_9jqV7zquTEIOpqndAl0Ch-7hZmjnF30tGQRSFUmCvqjPWCrqADuqTZ_fT6jLnTbEw6KHv4E11WkMtulbws8rc7NDPOLkYSLTE73Mc1zGP6yJppwgqp4kLZIcrF9AT6-ciYCZIBhe3mH6aRGxMJO4wOQxEYVAmfSJXZHQ-TiRPs96_rV5b9NlcPp4X1Y8vN9-vbxf3377eXV_dL1TDYVpAywauAZSpNbODKL9kujNiUEW2tKFK9Vo3fWsttQYNZ7QG3kMDYDUfTH1R3R25OuJGjsmVD-5lRCcPQkwriWlyyhvZ6oHXCNgZXjeDYSVNMGS6ZBS4EIX1-cga52FrtDJhSuhfQF--BLeWq7iTXdfXgrMC-PAISPHXbPIkty4r4z0GE-csGeNlbZR1vFjfP8_6G_K0p2IQR4NKMedkrFRuOmytRDsvgcqHWsiNPNRCPtRCHmtRZut_Zp_w_5v6A1mzv2k |
| CitedBy_id | crossref_primary_10_3892_ol_2022_13387 crossref_primary_10_1016_j_snb_2022_132493 crossref_primary_10_1111_jog_70026 crossref_primary_10_1080_07391102_2019_1696230 crossref_primary_10_1016_j_saa_2024_123923 crossref_primary_10_1002_anie_202313137 crossref_primary_10_1038_s41392_020_00367_5 crossref_primary_10_1002_ange_202313137 |
| Cites_doi | 10.12659/MSM.882046 10.1007/s13277-010-0123-8 10.1002/path.1000 10.1111/his.12033 10.1111/j.1600-0412.2011.01114.x 10.1056/NEJM198310133091503 10.1097/PAS.0b013e3181cf3d79 10.1001/jama.280.8.719 10.1093/oxfordjournals.humrep.a136832 10.1159/000444321 10.4161/auto.3909 10.4103/0973-1482.157335 10.1042/bj2910677 10.1016/j.ajpath.2015.11.011 10.1002/ijc.29665 10.3109/02841869709001350 |
| ContentType | Journal Article |
| Copyright | 2019 The Authors 2019 |
| Copyright_xml | – notice: 2019 The Authors 2019 |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1016/j.eurox.2019.100012 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Open Access Full Text url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2590-1613 |
| ExternalDocumentID | oai_doaj_org_article_5db73a1a6e734be2b9192a2d0ccf0f99 PMC6683972 31396597 10_1016_j_eurox_2019_100012 |
| Genre | Journal Article |
| GroupedDBID | 0R~ 53G AAEDW AALRI AAXUO AAYWO AAYXX ACVFH ADBBV ADCNI ADVLN AEUPX AEXQZ AFJKZ AFPUW AFTJW AIGII AITUG AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS APXCP BCNDV CITATION EBS EJD FDB GROUPED_DOAJ HYE M41 OK1 ROL RPM SSZ NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c471t-152b7d11ce3d2fb91392d6e9bcb7df040cc8dd485ff0feae72031781411fd7be3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 14 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001147494400002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2590-1613 |
| IngestDate | Fri Oct 03 12:53:11 EDT 2025 Thu Aug 21 18:16:05 EDT 2025 Thu Jul 10 19:25:32 EDT 2025 Thu Apr 03 06:52:04 EDT 2025 Thu Nov 20 00:30:19 EST 2025 Tue Nov 18 22:26:55 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | CA125 Adnexal mass Endometrioid ovarian cancer Lysophosphatidic acid |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c471t-152b7d11ce3d2fb91392d6e9bcb7df040cc8dd485ff0feae72031781411fd7be3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://doaj.org/article/5db73a1a6e734be2b9192a2d0ccf0f99 |
| PMID | 31396597 |
| PQID | 2270010267 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_5db73a1a6e734be2b9192a2d0ccf0f99 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6683972 proquest_miscellaneous_2270010267 pubmed_primary_31396597 crossref_citationtrail_10_1016_j_eurox_2019_100012 crossref_primary_10_1016_j_eurox_2019_100012 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-04-01 |
| PublicationDateYYYYMMDD | 2019-04-01 |
| PublicationDate_xml | – month: 04 year: 2019 text: 2019-04-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | European journal of obstetrics & gynecology and reproductive biology: X |
| PublicationTitleAlternate | Eur J Obstet Gynecol Reprod Biol X |
| PublicationYear | 2019 |
| Publisher | Elsevier |
| Publisher_xml | – name: Elsevier |
| References | Calis (10.1016/j.eurox.2019.100012_bib0050) 2016; 81 Kurman (10.1016/j.eurox.2019.100012_bib0025) 2010; 34 Terzi (10.1016/j.eurox.2019.100012_bib0045) 2015; 36 He (10.1016/j.eurox.2019.100012_bib0040) 2011; 17 Orfanelli (10.1016/j.eurox.2019.100012_bib0080) 2015; 137 Piek (10.1016/j.eurox.2019.100012_bib0020) 2001; 195 Xu (10.1016/j.eurox.2019.100012_bib0055) 1998; 280 Radosa (10.1016/j.eurox.2019.100012_bib0005) 2011 Jacobs (10.1016/j.eurox.2019.100012_bib0010) 1989; 4 Kurman (10.1016/j.eurox.2019.100012_bib0090) 2016; 186 Eichholitz (10.1016/j.eurox.2019.100012_bib0095) 1993; 291 Bast (10.1016/j.eurox.2019.100012_bib0015) 1983; 309 Cibula (10.1016/j.eurox.2019.100012_bib0030) 2011; 90 Gurung (10.1016/j.eurox.2019.100012_bib0085) 2013; 62 Sarandakou (10.1016/j.eurox.2019.100012_bib0035) 1997; 36 Zhang (10.1016/j.eurox.2019.100012_bib0070) 2015; 11 Fang (10.1016/j.eurox.2019.100012_bib0060) 2002; 23 Sedlakova (10.1016/j.eurox.2019.100012_bib0065) 2011; 32 Chang (10.1016/j.eurox.2019.100012_bib0075) 2007; 3 |
| References_xml | – volume: 17 start-page: CR618 issue: 11 year: 2011 ident: 10.1016/j.eurox.2019.100012_bib0040 article-title: Determination of CA-125 levels in the serum, cervical and vaginal secretions, and endometrium in Chinese women with precancerous disease or endometrial cancer publication-title: Med Sci Monit doi: 10.12659/MSM.882046 – volume: 32 start-page: 311 year: 2011 ident: 10.1016/j.eurox.2019.100012_bib0065 article-title: Lysophosphatidic acid (LPA) – a perspective marker in ovarian cancer publication-title: Tumor Biol doi: 10.1007/s13277-010-0123-8 – start-page: 1956 issue: 21 year: 2011 ident: 10.1016/j.eurox.2019.100012_bib0005 article-title: Preoperative multimodal strategies for risk assessment of adnexal masses. Analysis of 1362 cases in a gynecologic cancer center publication-title: Int J Gynecol Cancer – volume: 195 start-page: 451 year: 2001 ident: 10.1016/j.eurox.2019.100012_bib0020 article-title: Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer publication-title: J Pathol doi: 10.1002/path.1000 – volume: 62 start-page: 59 year: 2013 ident: 10.1016/j.eurox.2019.100012_bib0085 article-title: Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates publication-title: Histopathol doi: 10.1111/his.12033 – volume: 90 start-page: 559 year: 2011 ident: 10.1016/j.eurox.2019.100012_bib0030 article-title: Underlying mechanisms of ovarian cancer risk reduction after tubal ligation publication-title: Acta Obstet Gynecol doi: 10.1111/j.1600-0412.2011.01114.x – volume: 309 start-page: 883 year: 1983 ident: 10.1016/j.eurox.2019.100012_bib0015 article-title: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer publication-title: N Eng J Med doi: 10.1056/NEJM198310133091503 – volume: 34 start-page: 433 year: 2010 ident: 10.1016/j.eurox.2019.100012_bib0025 article-title: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory publication-title: Am J Surg Pathol doi: 10.1097/PAS.0b013e3181cf3d79 – volume: 280 start-page: 719 year: 1998 ident: 10.1016/j.eurox.2019.100012_bib0055 article-title: Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers publication-title: JAMA doi: 10.1001/jama.280.8.719 – volume: 23 start-page: 57 year: 2002 ident: 10.1016/j.eurox.2019.100012_bib0060 article-title: Lysophosphatidic acid is a bioactive mediator in ovarian cancer publication-title: Biochim Biophys Acta – volume: 36 start-page: 560 issue: 5 year: 2015 ident: 10.1016/j.eurox.2019.100012_bib0045 article-title: New method: Are tumor markers in vaginal-washing fluid significant in the diagnosis of primary ovarian carcinoma? publication-title: Eur J Gynaecol Oncol – volume: 4 start-page: 1 year: 1989 ident: 10.1016/j.eurox.2019.100012_bib0010 article-title: The CA 125 tumor-associated antigen: a review of the literature publication-title: Hum Reprod doi: 10.1093/oxfordjournals.humrep.a136832 – volume: 81 start-page: 518 year: 2016 ident: 10.1016/j.eurox.2019.100012_bib0050 article-title: Assessment of cervicovaginal cancer antigen 125 levels: A preliminary study for endometrial cancer screening publication-title: Gynecol Obstet Invest doi: 10.1159/000444321 – volume: 3 start-page: 268 issue: 3 year: 2007 ident: 10.1016/j.eurox.2019.100012_bib0075 article-title: Lysophosphatidic acid inhibits serum deprivation-induced autophagy in human prostate cancer PC-3 cells publication-title: Autophagy doi: 10.4161/auto.3909 – volume: 11 start-page: 375 issue: 2 year: 2015 ident: 10.1016/j.eurox.2019.100012_bib0070 article-title: Clinical significance of plasma lysophosphatidic acid levels in the differential diagnosis of ovarian cancer publication-title: J Cancer Res Ther doi: 10.4103/0973-1482.157335 – volume: 291 start-page: 677 year: 1993 ident: 10.1016/j.eurox.2019.100012_bib0095 article-title: The bioactive phospholipid lysophosphatidic acid is released from activated platelets publication-title: Biochem J doi: 10.1042/bj2910677 – volume: 186 start-page: 733 issue: 4 year: 2016 ident: 10.1016/j.eurox.2019.100012_bib0090 article-title: The dualistic model of ovarian carcinogenesis revisited, revised, and expanded publication-title: Am J Pathol doi: 10.1016/j.ajpath.2015.11.011 – volume: 137 start-page: 2879 year: 2015 ident: 10.1016/j.eurox.2019.100012_bib0080 article-title: Inhibition of autophagy in peripheral blood mononuclear cells by vaginal fluid from women with a malignant adnexal mass publication-title: Int J Cancer doi: 10.1002/ijc.29665 – volume: 36 start-page: 755 issue: 7 year: 1997 ident: 10.1016/j.eurox.2019.100012_bib0035 article-title: Vaginal fluid and serum CEA, CA125 and SCC in normal conditions and in benign and malignant diseases of the genital tract publication-title: Acta Oncol doi: 10.3109/02841869709001350 |
| SSID | ssj0002181861 |
| Score | 2.3304112 |
| Snippet | There remains a need to differentiate between women with a benign or a malignant adnexal mass prior to surgery. As part of an ongoing evaluation of vaginal... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 100012 |
| SubjectTerms | Gynaecology: Oncology |
| Title | Evaluation of lysophosphatidic acid in vaginal fluid as a biomarker for ovarian cancer: A pilot study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31396597 https://www.proquest.com/docview/2270010267 https://pubmed.ncbi.nlm.nih.gov/PMC6683972 https://doaj.org/article/5db73a1a6e734be2b9192a2d0ccf0f99 |
| Volume | 2 |
| WOSCitedRecordID | wos001147494400002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Open Access Full Text customDbUrl: eissn: 2590-1613 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002181861 issn: 2590-1613 databaseCode: DOA dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB5BhRAXxLsppTISRyJiJxvHvbWoFRcqDiDtzfJTDVolq32J_vvOONnVLkJw4eo4iTUzznzWTL4P4IOz0avSy9wXMuSV9JO8mZCYGffCIr72qo5JbELe3DTTqfq2J_VFPWEDPfBguE8Tb2VpuKmDLCsb8AGISYzwhXOxiCr9uldItXeYom8wJa4mkaUivC9yhDXllnIoNXcR8cUvauxS1CZQcHGQlhJ7_58g5--dk3up6PoZPB0xJLsY1v4cHoTuBTz-OlbJX0K42lF4sz6y2R1JFfTL-S0O4RxmXOtZ27GNSZpYLM7WOGCWzDD6G58adhYMwSzrN3iSNh1zFBqLc3bB5u2sX7HESfsKflxfff_8JR_lFHKHGWiVY6a20nPuQulFtMQHKnwdlHU4HHEzO9d4XzWTiIYNJlCBlhMjFufRSxvK13DU9V04BlaFSiBWqKxXFhFfbbiIsXGuto7YclQGYmtN7UaucZK8mOltU9lPnVygyQV6cEEGH3c3zQeqjb9PvyQ37aYST3YawOjRY_Tof0VPBu-3Tta4r6hYYrrQr5dapIo86XNl8GZw-u5VJZquxpNYBvIgHA7Wcnila28Td3ddIyKV4uR_LP4tPCF7DH1Ep3C0WqzDO3jkNqt2uTiDh3LanKVtcQ8uyxJj |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+lysophosphatidic+acid+in+vaginal+fluid+as+a+biomarker+for+ovarian+cancer%3A+A+pilot+study&rft.jtitle=European+journal+of+obstetrics+%26+gynecology+and+reproductive+biology%3A+X&rft.au=Minis%2C+Evelyn&rft.au=Holcomb%2C+Kevin&rft.au=Sisti%2C+Giovanni&rft.au=Nasioudis%2C+Dimitrios&rft.date=2019-04-01&rft.issn=2590-1613&rft.eissn=2590-1613&rft.volume=2&rft.spage=100012&rft_id=info:doi/10.1016%2Fj.eurox.2019.100012&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_eurox_2019_100012 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2590-1613&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2590-1613&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2590-1613&client=summon |